We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hospira’s McPherson, Kansas manufacturing plant was cited for numerous deficiencies found during an FDA inspection, many of them repeat issues from an earlier inspection. Read More
Once hailed by President Trump and others as a possible treatment for COVID-19, the antimalarial drug hydroxychloroquine continues to a thumbs down in a number of human studies, most recently for treatment of patients with mild infections and for hospitalized patients. Read More
Democrats on the House’s coronavirus crisis subcommittee have launched an investigation into federal contracts for producing drugs, drug ingredients and supplies essential in the pandemic that they claim have been awarded to businesses politically tied to the Trump administration “without competition or transparency.” Read More
Johnson & Johnson has announced that it will begin evaluating its experimental COVID-19 vaccine in its first clinical trial next week, beginning in Belgium on July 22 and the U.S. the following week. Read More
As research on COVID-19 vaccines advances at an unprecedented pace, Russian hackers have been attempting to steal research information, the UK’s National Cyber Security Centre (NCSC) reported Thursday. Read More
The FDA cited over-the-counter (OTC) drug manufacturer Eosera for failing to conduct process validations and other lapses at its Fort Worth, Texas facility. Read More